We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Intarcia Therapeutics Stock

Invest in or calculate the value of your shares in Intarcia Therapeutics or other pre-IPO companies through EquityZen's platform.

Get Started

Intarcia Therapeutics Stock

Intarcia Therapeutics is a biopharmaceutical company developing therapies for diseases that require long-term chronic treatment.

About Intarcia Therapeutics Stock

Founded

1997

Total Funding

1.1B

Industries

Science and Engineering, Health Care, Biotechnology

Intarcia Therapeutics, Inc. is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. The company's products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. The company was formerly known as BioMedicines, Inc. and changed its name to Intarcia Therapeutics, Inc. in September 2004. Intarcia Therapeutics was founded in 1997 and is based in Hayward, California with an additional office in Mountain View, California.

Investors in Intarcia Therapeutics

Discover investors in Intarcia Therapeutics stock and explore their portfolio companies

Intarcia Therapeutics Management

Leadership team at Intarcia Therapeutics

CFO & Vice President, Finance and Operations

James M. Ahlers

Vice President, Global Regulatory Affairs and Quality

Sunita Zalani

Locked Features

Join now and verify your accreditation status to gain access to:

  • Intarcia Therapeutics current valuation
  • Intarcia Therapeutics stock price
  • Available deals in Intarcia Therapeutics and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Intarcia Therapeutics stock?

Accredited investors can buy pre-IPO stock in companies like Intarcia Therapeutics through EquityZen funds. These investments are made available by existing Intarcia Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Intarcia Therapeutics stock?

Shareholders can sell their Intarcia Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 310K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."